Glass Pharms, the UK-based licensed cultivator of medical cannabis, has announced a new partnership with Mamedica, one of the country’s leading private medical cannabis clinics.
Under the collaboration, Glass Pharms will supply high-quality cannabis flower for use in Mamedica-branded, clinician-prescribed products, reinforcing the value of a fully domestic supply chain for CBPMs (Cannabis-Based Products for Medicinal Use).
Glass Pharms currently cultivates a diverse range of cannabis flower, encompassing 14 cultivars with distinct cannabinoid and terpene profiles. Among these is a THC:CBD balanced cultivar that has successfully achieved the rigorous 5.1.4 microbial standard without irradiation, a milestone in UK cultivation.
“We’re proud to support UK cultivation, and the quality of this flower meets the high standards our patients expect from Mamedica.” – Jon Robson, CEO and Founder of Mamedica
Mamedica has already incorporated several Glass Pharms-derived products into its prescribing framework this year. Following strong clinical performance and supply consistency, one of Glass Pharms’ most frequently prescribed flowers will now feature as part of Mamedica’s own-livery product line.
“Expanding the range of cannabis flower choices for prescribing options to meet all clinical needs is important to Glass Pharms and we are happy to announce this new partnership with Mamedica’, said James Duckenfield, Glass Pharms’ CEO.
Glass Pharms products are now prescribed across a growing number of UK clinics, including Mamedica, Curaleaf, Releaf, Integro, CB1, Lyphe, and others.
Jon Robson and James Duckenfield will be speaking at Cannabis Europa on June 25th during the panel ‘Domestic vs Import: Does it Really Matter for Medical Cannabis Supply?’. Glass Pharms has also been shortlisted for ‘Producer of the Year’ at the upcoming Business of Cannabis Awards on June 24th.
